ABCL - AbCellera Biologics Inc

3.45
-0.140   -4.058%

Share volume: 4,246,409
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.26%

PREVIOUS CLOSE
CHG
CHG%
$3.59
-0.14
-0.04%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
39%
Profitability 35%
Dept financing 24%
Liquidity 50%
Performance 44%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-9.69%
1 Month
7.14%
3 Months
-3.90%
6 Months
-17.27%
1 Year
48.07%
2 Year
-29.74%
Key data
Stock price
$3.45
P/E Ratio 
0.00
DAY RANGE
$3.41 - $3.56
EPS 
-$0.48
52 WEEK RANGE
$1.89 - $6.52
52 WEEK CHANGE
$56.82
MARKET CAP 
1.024 B
YIELD 
N/A
SHARES OUTSTANDING 
303.160 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-08-2025
BETA 
1.27
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$4,685,810
AVERAGE 30 VOLUME 
$4,227,682
Company detail
CEO: Carl Lars G. Hansen
Region: US
Website: abcellera.com
Employees: 500
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

AbCellera Biologics Inc. has 156 discovery programs that are either completed, in progress, or under contract with 36 partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Recent news